News & Updates

Exposure to wildfire smoke for an extended period may increase the risk of heart failure (HF) in older adults, particularly women and socially vulnerable populations, suggests a study.

A short-course antibiotic treatment for children with community-acquired pneumonia (CAP) demonstrates effectiveness similar to the long-course regimen but with fewer serious adverse events (AEs), reports a study.

Acute respiratory infections (ARIs) are associated with various symptoms across different age groups, according to a Korea study.

New drug applications approved by US FDA as of 16-31 May 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

In the treatment of adults with acute, uncomplicated influenza infections, onradivir appears to provide similar curative efficacy as oseltamivir while having an acceptable safety profile, as shown in a phase III study.

Hypoglossal nerve stimulation is safe and effective for reducing apnoea-hypopnoea index (AHI) in Asian patients with obstructive sleep apnoea (OSA), according to early experience from a single tertiary Singaporean sleep centre.

The bispecific antibody gremubamab, which targets two proteins on the surface of Pseudomonas aeruginosa, has been shown to substantially reduce bacterial load and improve quality of life for infected bronchiectasis patients in the phase II GREAT-2 study.

The investigational influenza–COVID-19 combination vaccine mRNA-1083 has demonstrated noninferiority to recommended standard-care flu and COVID-19 vaccines, with higher immune responses and an acceptable safety profile in adults at least 50 years of age, according to the results of a phase III trial.